A recent industry spotlight by Venkat Mutavi notes a sobering statistic: nearly half of all pharmaceutical launches miss their peak sales forecasts by more than 20%. For the global C-suite, this is a systemic crisis. In the United States and Europe, where "precision" medicine is the standard, a 20% deviation can be the difference between a blockbuster ROI and a pipeline-killing failure.
But in the domestic Indian market? A 20% gap is often just statistical noise.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
